000112646 001__ 112646
000112646 005__ 20190213070413.0
000112646 02470 $$2DAR$$a11409
000112646 02470 $$2ISI$$a000250928300002
000112646 037__ $$aARTICLE
000112646 245__ $$aAccess to vaccine technologies in developing countries: Brazil and India
000112646 269__ $$a2007
000112646 260__ $$c2007
000112646 336__ $$aJournal Articles
000112646 520__ $$aThis study, conducted by visits, interviews, and literature search, analyzes how vaccine manufacturers in Brazil and India access technologies for innovative vaccines: through collaborations with academia and research institutions, technology transfer agreements with multinational corporations, public sector, or developing country organizations, or by importation and finishing of bulk products. Each has advantages and disadvantages in terms of speed, market, and ability to independently produce the product. Most manufacturers visited are very concerned about avoiding patent infringement, which might result in undeveloped or delayed products because of a lack of mastery of the patent landscape. Disregarding the patent picture could also threaten the market of a potential product. Although it is too soon to assess the effects of TRIPS on vaccine technology access in Brazil and India, a good understanding of intellectual property management will be useful. A case study on development of a new combination vaccine illustrates these findings.
000112646 6531_ $$avaccine innovation
000112646 6531_ $$aintellectual property rights
000112646 6531_ $$atechnology transfer
000112646 700__ $$aMilstien, Julie B.
000112646 700__ $$0240633$$aGaulé, Patrick$$g171089
000112646 700__ $$aKaddar, Miloud
000112646 773__ $$j25$$k44$$q7610-7619$$tVaccine
000112646 8564_ $$uhttp://www.sciencedirect.com/science/journal/0264410X$$zURL
000112646 909C0 $$0252155$$pCEMI$$xU11004
000112646 909CO $$ooai:infoscience.tind.io:112646$$pCDM$$particle
000112646 937__ $$aCEMI-ARTICLE-2007-005
000112646 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000112646 980__ $$aARTICLE